Evidence map›Paper›PMID 38005304›Full record

ArticleMolecules (Basel, Switzerland)2023

The Protective Effect of

Zhiguang Zhang, Boya Liang, Wugemo Jike, Runtian Li, Xinxin Su, Jie Yu, Tongxiang Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Biomarker Discovery and Molecular Docking RevealCurrent issues in molecular biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhiguang ZhangSchool of Pharmacy, Minzu University of China, Beijing 100081, China.
Boya LiangSchool of Pharmacy, Minzu University of China, Beijing 100081, China.
Wugemo JikeSchool of Pharmacy, Minzu University of China, Beijing 100081, China.
Runtian LiSchool of Pharmacy, Minzu University of China, Beijing 100081, China.
Xinxin SuSchool of Pharmacy, Minzu University of China, Beijing 100081, China.
Jie YuSchool of Pharmacy, Minzu University of China, Beijing 100081, China.
Tongxiang LiuSchool of Pharmacy, Minzu University of China, Beijing 100081, China.ORCID 0000-0001-5655-7877
Minzu University of China · CN

Funding

National Natural Science Foundation of China 81973977
6 · The paper itself

Abstract

Cisplatin (Cis) is considered to be one of the most effective drugs for killing cancer cells and remains a first-line chemotherapeutic agent. However, Cis's multiple toxicities (especially nephrotoxicity) have limited its clinical use.

Indexed as

CisplatinMarsdeniaAnimalsAntioxidantsApoptosisCaspase 3I-kappa B KinaseInflammationMiceNF-E2-Related Factor 2NF-kappa BOxidative StressProto-Oncogene Proteins c-bcl-2AntioxidantsCaspase 3CisplatinI-kappa B KinaseNF-E2-Related Factor 2NF-kappa BProto-Oncogene Proteins c-bcl-2apoptosiscisplatininflammationMarsdenia tenacissimanephrotoxicityoxidative stress

Identifiers

PMID38005304
PMCPMC10674371
OpenAlexW4388654854

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.